Ruggero Capra Selected Research

Progressive Multifocal Leukoencephalopathy

5/2021	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
1/2021	Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
1/2020	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
1/2020	Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
10/2019	Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
1/2019	Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
1/2018	Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue."
11/2017	To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.
10/2017	Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
10/2017	Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopathy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ruggero Capra Research Topics

Disease

43	Multiple Sclerosis 10/2022 - 09/2007
19	Progressive Multifocal Leukoencephalopathy 05/2021 - 09/2013
9	Relapsing-Remitting Multiple Sclerosis 07/2021 - 02/2010
6	Infections 10/2022 - 02/2010
5	COVID-19 10/2022 - 01/2020
4	Disease Progression 01/2020 - 01/2016
4	Immune Reconstitution Inflammatory Syndrome 01/2019 - 01/2017
3	Neuromyelitis Optica (Devic's Disease) 01/2020 - 10/2017
2	Sudden Infant Death (SID) 05/2021 - 01/2020
2	Pneumonia (Pneumonitis) 08/2020 - 01/2020
2	Respiratory Insufficiency (Respiratory Failure) 08/2020 - 01/2020
2	Inflammation (Inflammations) 08/2020 - 01/2018
2	Demyelinating Diseases (Demyelinating Disease) 01/2018 - 12/2017
2	Opportunistic Infections (Opportunistic Infection) 10/2017 - 01/2016
2	Cognitive Dysfunction 01/2015 - 03/2002
1	Chronic Progressive Multiple Sclerosis 01/2021
1	Leukoencephalopathies 01/2021
1	Seizures (Absence Seizure) 01/2019
1	Paratuberculosis (Johne's Disease) 01/2018
1	Cardiotoxicity 05/2013
1	Leukopenia 12/2011
1	Macular Edema 02/2010
1	Herpesviridae Infections (Herpesvirus Infection) 02/2010
1	Bradycardia 02/2010
1	Herpes Zoster 02/2010
1	Atrioventricular Block 02/2010
1	Chickenpox 02/2010
1	Herpes Simplex Encephalitis (Herpes Encephalitis) 02/2010
1	Hypertension (High Blood Pressure) 02/2010
1	Skin Neoplasms (Skin Cancer) 02/2010
1	Microscopic Polyangiitis 03/2002
1	Dementia (Dementias) 03/2002
1	Churg-Strauss Syndrome (Allergic Angiitis) 03/2002
1	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 03/2002
1	Vasculitis (Vasculitides) 03/2002

Drug/Important Bio-Agent (IBA)

26	Natalizumab (Tysabri)FDA Link 01/2022 - 01/2012
7	nitazoxanide (NTZ)FDA Link 10/2019 - 11/2015
5	InterferonsIBA 01/2022 - 02/2010
5	Monoclonal AntibodiesIBA 01/2021 - 10/2012
5	Interferon-betaIBA 01/2015 - 06/2008
4	ocrelizumabIBA 10/2022 - 01/2021
4	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 02/2010
4	AntibodiesIBA 01/2021 - 09/2007
4	Biomarkers (Surrogate Marker)IBA 01/2018 - 09/2013
3	Alemtuzumab (Campath)FDA Link 01/2022 - 01/2019
3	Messenger RNA (mRNA)IBA 01/2014 - 06/2008
2	Antiviral Agents (Antivirals)IBA 10/2022 - 01/2022
2	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2018
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2020 - 12/2011
2	tocilizumab (atlizumab)FDA Link 08/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2016
2	CytokinesIBA 01/2018 - 01/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2015
2	AntigensIBA 01/2018 - 10/2017
2	SteroidsIBA 11/2017 - 01/2017
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2017 - 12/2014
2	Interferon beta-1a FDA Link 01/2015 - 02/2010
2	Staphylococcal Protein A (Protein A)IBA 01/2014 - 09/2010
1	Glatiramer Acetate (Copaxone)FDA Link 01/2022
1	Cladribine FDA LinkGeneric 01/2022
1	Influenza Vaccines (Influenza Vaccine)FDA Link 04/2021
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 08/2020
1	Ritonavir (Norvir)FDA Link 08/2020
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 08/2020
1	Lopinavir FDA Link 08/2020
1	Therapeutic UsesIBA 01/2020
1	factor AIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	N-formylmethionylphenylalanine (FMP)IBA 11/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Myelin Basic ProteinIBA 01/2018
1	Interleukin-2 (IL2)IBA 01/2018
1	EpitopesIBA 01/2018
1	Interleukin-10 (Interleukin 10)IBA 01/2018
1	Myelin-Oligodendrocyte GlycoproteinIBA 12/2017
1	Glycoproteins (Glycoprotein)IBA 10/2017
1	Peptides (Polypeptides)IBA 10/2017
1	Maraviroc FDA Link 07/2017
1	MS 28IBA 01/2016
1	AntipyreticsIBA 01/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015
1	Neutralizing AntibodiesIBA 02/2014
1	Biological ProductsIBA 01/2014
1	Mitoxantrone (Novantrone)FDA LinkGeneric 05/2013
1	IntegrinsIBA 01/2012
1	EnzymesIBA 02/2010
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 03/2002

Therapy/Procedure

13	Therapeutics 01/2021 - 06/2008
6	Cognitive Training 02/2016 - 01/2010
1	Artificial Respiration (Mechanical Ventilation) 01/2020
1	Blood Component Removal (Apheresis) 01/2018
1	Plasma Exchange 11/2017
1	Injections 02/2017
1	Plasmapheresis 01/2017
1	Transcranial Direct Current Stimulation 02/2016